Cargando…

Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer

The prevalence of TP53 mutations in advanced prostate cancers (PCa) is 3 to 5 times of the quantity in primary PCa. By an integrative analysis of the Cancer Genome Atlas and Catalogue of Somatic Mutations in Cancer data, we revealed the supporting evidence for 2 complementary hypotheses: H(1) - TP53...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wensheng, Dong, Yan, Sartor, Oliver, Zhang, Kun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980432/ https://www.ncbi.nlm.nih.gov/pubmed/35392296 http://dx.doi.org/10.1177/11769351221087046

Ejemplares similares

SEER and Gene Expression Data Analysis Deciphers Racial Disparity Patterns in Prostate Cancer Mortality and the Public Health Implication
por: Zhang, Wensheng, et al.
Publicado: (2020)

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
por: Zhang, Wensheng, et al.
Publicado: (2017)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
por: Zhou, Jie, et al.
Publicado: (2022)

TP53 structural variants in metastatic prostatic carcinoma
por: Sirohi, Deepika, et al.
Publicado: (2019)

A transcriptomic signature for prostate cancer relapse prediction identified from the differentially expressed genes between TP53 mutant and wild-type tumors
por: Zhang, Wensheng, et al.
Publicado: (2022)

TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection
por: Klinakis, Apostolos, et al.
Publicado: (2020)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

TP53 mutations in Romanian patients with colorectal cancer
por: Manirakiza, Felix, et al.
Publicado: (2023)

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
por: Kim, Ji‐Yeon, et al.
Publicado: (2023)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
por: Bai, Han, et al.
Publicado: (2021)

The TP53 Codon 72 Arginine Polymorphism Is Found with Increased TP53 Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients
por: Moe, Svein Erik, et al.
Publicado: (2023)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer
por: Lahoz, Sara, et al.
Publicado: (2022)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

Modeling the prevalent germline TP53 R337H mutation in mouse
por: Park, Ji-Hoon, et al.
Publicado: (2019)

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer
por: Ghezelayagh, Talayeh S., et al.
Publicado: (2022)

Mutational processes shape the landscape of TP53 mutations in human cancer
por: Giacomelli, Andrew O., et al.
Publicado: (2018)

Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil
por: Giacomazzi, Juliana, et al.
Publicado: (2014)

TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk
por: Craig, Daniel J., et al.
Publicado: (2023)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Clinical implications of germline mutations in breast cancer: TP53
por: Schon, Katherine, et al.
Publicado: (2017)

TP53 Mutations Promote Immunogenic Activity in Breast Cancer
por: Liu, Zhixian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_imfjv24pn5da14dkm90aot6lfm